Innovation in immunomodulation

ImCheck Therapeutics is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells.  The company is  developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology. Our growing understanding of these novel targets has also identified unique opportunities in immune-mediated inflammatory disease also known as autoimmune diseases.

Latest news


ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
Financial & Business 
Read more
ImCheck Therapeutics awarded €2 million from Bpifrance to advance its first-in-class immunotherapy program into the clinic
Financial & Business 
Read more
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer
Leadership & Corporate 
Read more

Upcoming events


ASCO-SITC Clinical Immuno-Oncology Symposium 2020

From  Feb 06, 2020  to  Feb 08, 2020 

Read more

Immuno-oncology Summit Europe

From  Feb 09, 2020  to  Mar 12, 2020 

Read more

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress 2020

From  Mar 12, 2020  to  Mar 13, 2020 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and news